Biogen Idec (NASDAQ:BIIB)

biotech

Biogen Takes Breather on Earnings and MS Drug Sales

Biogen Idec Inc. (NASDAQ: BIIB) reported its third-quarter results before the market opened Wednesday as $3.80 in earnings per share and $2.5 billion in revenue. That was against Thomson Reuters ...
Read Full Story »
investor research

Cowen’s Sell-Off Shopping List Loaded With Stocks With Huge Upside Potential

As we mentioned last week, when the market sells off hard, the top firms on Wall Street usually circle the wagons and ask the analysts to come up with their ...
Read Full Story »
Biotechnology word cloud

Analyst Top Biotech Stocks Could Explode After Huge Sell-Off

When people are selling first and asking questions later, that is the exact time when savvy investors start to nibble at top stocks that have been hammered. As we reported ...
Read Full Story »
Biotechnology word cloud

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date. Biotech companies are considered a riskier group of stocks with big upside and big downside. FDA rulings ...
Read Full Story »
Cisco logo

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

After a 14-year secular bear market that finally ended when the S&P 500 broke solidly above the 1,600 level in the summer of last year, prompting a move to record ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
Wall St Bull statue

Credit Suisse Releases New Top Investment Ideas

With less than one-third of the year remaining, many portfolio managers at mutual funds and hedge funds are looking for some outperformance so they can catch up to whatever benchmark ...
Read Full Story »
biotech

Rising Short Interest in Biotech Stocks

The short interest data is out for the August 15 settlement date. Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts, ...
Read Full Story »
biotech

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

With the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back into the coverage world and have reinitiated research analysis on ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More

Stocks were indicated higher on Tuesday morning despite sanctions in Russia. Investors still want upside from their investments, but they seem to be looking at individual companies and sectors rather ...
Read Full Story »
Biotechnology word cloud

Top Biotech Earnings Previews for the Week Ahead

Earnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will ...
Read Full Story »
Stock Split Image

Will Celgene Trigger Other Biotech Stock Splits?

Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced ...
Read Full Story »